Research Focus

Former Employee. Research and Technology Management; NE Auditor

Recent additions – View all

1. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma

   Meeting Abstract

   Dickson, M. A.; Tap, W. D.; Keohan, M. L.; D'Angelo, S. P.; Gounder, M. M.; Chi, P.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Rathbone, D. D.; more...
   Journal of Clinical Oncology (2013)

   Fulltext@MSK | Save
2. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma

   Journal Article

   Dickson, M. A.; Tap, W. D.; Keohan, M. L.; D'Angelo, S. P.; Gounder, M. M.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Rathbone, D. D.; Condy, M. M.; more...
   Journal of Clinical Oncology (2013)

   Fulltext@MSK | Save
3. Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma

   Meeting Abstract

   Dickson, M. A.; Keohan, M. L.; Tap, W. D.; Antonescu, C.; Landa, J.; Qin, L. X.; Dohrenwend, E. G.; Rathbone, D.; Ustoyev, Y.; Condy, M. M.; more...
   Journal of Clinical Oncology (2012)

   Fulltext@MSK | Save